BlackRock Health Sciences Trust (BME) Fair Value 2026

BME · Asset Management ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.6 /10

32 fundamental signals · 2 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-28, BlackRock Health Sciences Trust (BME) trades at $45.88, versus a $88.88 median fair value across its 2 active models — 93.7% above the current price. QOC: 4.6/10. Value Trap Risk: 0/100 (SAFE). 2/13 models active.

Key Facts

Ticker
BME
Price
$45.88
Quality Score
4.6/10
Value Trap Risk
0/100
Models Active
2/13
Last Updated
Strength: Markov DDM suggests +139.6% upside with 16% confidence
Risk: Below-average Quality Score of 4.6/10 signals weak fundamentals

Is BlackRock Health Sciences Trust (BME) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, BlackRock Health Sciences Trust (BME) appears undervalued as of : the median of 2 independent fair value estimates is $88.88, 93.7% above the current price of $45.88. Estimates range from $67.84 to $109.92. BME scores 4.6/10 on fundamental quality and 0/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. BME’s +93.7% gap is wider than that market norm, and the Asset Management sector median is -4.4%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy BlackRock Health Sciences Trust Stock in 2026? →

What Fair Value Does Each Model Give BME?

2 Intrinsic Value Models vs. Current Price ($45.88)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $109.92 +139.6%
Relative · Low Conviction
 $67.84 +47.9%

All Models Active

All 2 models are displayed above.

What Is BlackRock Health Sciences Trust (BME) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, BlackRock Health Sciences Trust is potentially undervalued at its current price of $45.88. Based on our 13-model framework, BlackRock Health Sciences Trust's intrinsic value is estimated at a median fair value of $88.88 — representing +93.7% implied upside — with 2 out of 2 active models confirming this thesis. Model dispersion is worth noting: Markov DDM targets $109.92 (+139.6%), versus Regime Cross at $67.84 (+47.9%). This +91.7% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About BME?

2 of 13 models are currently active for BME. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for BME is $88.88 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does BME Rank in Asset Management?

Among 187 Asset Management stocks, BME ranks #140 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.

See all Most Undervalued Asset Management Stocks →

BlackRock Health Sciences Trust operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BME a Value Trap?

CirclFi's Value Trap algorithm assigns BME a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for BlackRock Health Sciences Trust. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, BlackRock Health Sciences Trust scores 4.6 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +91.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BME valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BME's 2 active models, average confidence is 14%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy BlackRock Health Sciences Trust Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Asset Management Stocks Should You Also Analyze?

11 related Asset Management stocks with 13-model coverage

BKTBlackRock Income Trust, Inc.QOC 4.7VLTInvesco High Income Trust IIQOC 4.6BDJBlackRock Enhanced Equity Dividend TrustQOC 4.7FINSAngel Oak Financial Strategies Income Term TrustQOC 4.6RVTRoyce Small-Cap Trust, Inc.QOC 4.7SDEVStablecoin Development CorporatQOC 4.6TBLDThornburg Income Builder Opportunities TrustQOC 2.2AMTDAMTD IDEA GroupQOC 6.9ASAASA Gold and Precious Metals LimitedQOC 5.4HLNEHamilton Lane IncorporatedQOC 9.3AMPAmeriprise Financial, Inc.QOC 9.3

Read investment analysis: BKT · VLT · BDJ · FINS · RVT · SDEV · TBLD · AMTD · ASA · HLNE · AMP

Which Other Stocks Have a Similar Quality Score to BME?

6 companies across all industries closest to BME’s Quality of Company score of 4.6/10.

NAKNorthern Dynasty Minerals Ltd.QOC 4.6BDRXBiodexa Pharmaceuticals PlcQOC 4.6AMBPArdagh Metal Packaging S.A.QOC 4.6ASTLAlgoma Steel Group Inc.QOC 4.6AQBAquaBounty Technologies, Inc.QOC 4.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NAK · BDRX · AMBP · ASTL · AQB · NVDA

Where Does BME Sit in CirclFi's Asset Management Rankings?

BME is ranked against every other Asset Management stock CirclFi covers in each of these screens.

See all Asset Management stocks ranked →

What Else Do Investors Ask About BlackRock Health Sciences Trust’s Valuation?

What is BlackRock Health Sciences Trust's intrinsic value in 2026?

CirclFi puts BlackRock Health Sciences Trust (BME)'s intrinsic value at $88.88 — the median of 2 independent model estimates as of 2026-08-28, ranging from $67.84 to $109.92. The Quality of Company score is 4.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BME overvalued or undervalued right now?

At $45.88, 2 of 2 active models suggest BME may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $88.88, 93.7% above the current price of $45.88 — a consensus view that BME is undervalued. The assessment depends on which methodology best fits BlackRock Health Sciences Trust's business model in Asset Management.

What does a Quality of Company score of 4.6 mean for BME?

BlackRock Health Sciences Trust's QOC of 4.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BME?

CirclFi analyzes BME with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is BME a value trap in 2026?

BlackRock Health Sciences Trust's Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, BlackRock Health Sciences Trust (BME) has a median fair value of $88.88 — 93.7% above the current price of $45.88 — as of 2026-08-28.” Source: circlfi.com/stock/BME/ · Methodology
Primary sources for this BME valuation
  • Financial statements: BlackRock Health Sciences Trust 10-K and 10-Q filings on SEC EDGAR (CIK 0001314966) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BME as of ; valuations recomputed .